Glutamate receptor modulator - Boehringer Ingelheim
Latest Information Update: 05 May 2025
At a glance
- Originator Boehringer Ingelheim
- Class Neuropsychotherapeutics
- Mechanism of Action Glutamate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Mental disorders
Most Recent Events
- 24 Apr 2025 Phase-I clinical trials in Mental disorders (unspecified route) before April 2025 (Boehringer Ingelheim pipeline, April 2025)